By Michael Dabaie

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. said the Phase 3 Discover 1 and 2 studies, which evaluated guselkumab compared to placebo in adult patients with active moderate to severe psoriatic arthritis, met their primary endpoints.

The studies met the goal of American College of Rheumatology 20% improvement, and the safety profiles observed for guselkumab in the program were consistent with previous studies of guselkumab and current prescribing information, Janssen said.

Data from the two studies will serve as the basis of submissions to the U.S. Food and Drug Administration and European Medicines Agency seeking approval of guselkumab as a treatment for psoriatic arthritis, which are anticipated for later this year.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

June 14, 2019 08:21 ET (12:21 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Johnson and Johnson.
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Johnson and Johnson.